1.Positron Emission Tomography with Fluorine-18-Fluorodeoxyglucose is Useful for Predicting the Prognosis of Patients with Hepatocellular Carcinoma.
Yun Ho KONG ; Chul Ju HAN ; Sang Dae LEE ; Wee Sik SOHN ; Min Jae KIM ; Seung Seog KI ; Jin KIM ; Sook Hyang JEONG ; You Cheoul KIM ; Jhin Oh LEE ; Gi Jeong CHEON ; Chang Woon CHOI ; Sang Moo LIM
The Korean Journal of Hepatology 2004;10(4):279-287
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is heterogenous in terms of its glucose metabolism. Positron emission tomography with fluorine-18-fluorodeoxyglucose (FDG-PET) shows various levels of FDG uptake for patients with HCC. This study was designed to assess the usefulness of FDG-PET for predicting the outcome of the patients with HCC. METHODS: FDG-PET was performed for 27 patients with HCC. The standardized uptake value (SUV) and SUV ratio (defined as the tumor-to-nontumor ratio of SUV) was calculated for each patient. The clinical factors of the outcome were analyzed by regression analysis using Cox's multivariate proportional hazard model. The survival rate was calculated by the Kaplan-Meier method. RESULTS: Among the analyzed clinical factors including tumor size, number of tumors, AFP, involvement of major vessels, presence of systemic metastases, Child-Pugh class the SUV and SUV ratio, only the SUV was the only significant independent prognostic factor (p=0.001). On the basis of the SUV, the patients were divided into two groups of roughly equal size: group A, SUV of <7; group B, SUV >or=7. The cumulative survival rate was significantly lower for group B than for group A, and the median survival time was significantly different (4 months vs 15 months, respectively) (p=0.003). CONCLUSIONS: These results suggest that FDG-PET is useful to predict the outcome for patients with hepatocellular carcinoma.
Adult
;
Aged
;
Carcinoma, Hepatocellular/mortality/*radionuclide imaging
;
English Abstract
;
Female
;
Fluorodeoxyglucose F18/*diagnostic use
;
Humans
;
Liver Neoplasms/mortality/*radionuclide imaging
;
Male
;
Middle Aged
;
*Positron-Emission Tomography
;
Prognosis
;
Radiopharmaceuticals/*diagnostic use
;
Survival Rate
2.Use of 18F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.
Min Jin KIM ; Young Seok KIM ; Youn Hee CHO ; Hee Yoon JANG ; Jeong Yeop SONG ; Sae Hwan LEE ; Soung Won JEONG ; Sang Gyune KIM ; Jae Young JANG ; Hong Su KIM ; Boo Sung KIM ; Won Hyung LEE ; Jung Mi PARK ; Jae Myung LEE ; Min Hee LEE ; Deuk Lin CHOI
The Korean Journal of Internal Medicine 2015;30(3):308-315
BACKGROUND/AIMS: 18F-Fluorodeoxyglucose positron-emission tomography (18F-FDG PET) has been used to assess the biological behavior of hepatocellular carcinoma (HCC). In this study, we investigated the usefulness of 18F-FDG PET for predicting tumor progression and survival in patients with intermediate Barcelona Clinic Liver Cancer (BCLC) intermediate-stage HCC treated by transarterial chemoembolization (TACE). METHODS: From February 2006 to March 2013, 210 patients treated with TACE, including 77 patients with BCLC intermediate-stage HCC, underwent examination by 18F-FDG PET. 18F-FDG uptake was calculated based on the tumor maximum (Tmax) standardized uptake value (SUV), the liver mean (Lmean) SUV, and the ratio of the Tmax SUV to the Lmean SUV (Tmax/Lmean). RESULTS: The mean follow-up period for the 77 patients (52 males, 25 females; average age, 63.3 years) was 22.2 months. The median time to progression of HCC in patients with a low Tmax/Lmean (< 1.83) and high Tmax/Lmean (> or = 1.83) was 17 and 6 months, respectively (p < 0.001). The median overall survival time of patients with a low and high Tmax/Lmean was 44 and 14 months, respectively (p = 0.003). Multivariate analysis revealed that the Tmax/Lmean was an independent predictor of overall survival (hazard ratio [HR], 1.96; 95% confidence interval [CI], 1.210 to 3.156; p = 0.006) and tumor progression (HR, 2.05; 95% CI, 1.264 to 3.308; p = 0.004). CONCLUSIONS: 18F-FDG uptake calculated by the Tmax/Lmean using PET predicted tumor progression and survival in patients with BCLC intermediate-stage HCC treated by TACE.
Aged
;
Carcinoma, Hepatocellular/mortality/*radionuclide imaging/*surgery
;
*Chemoembolization, Therapeutic/adverse effects/mortality
;
Disease Progression
;
Female
;
*Fluorodeoxyglucose F18
;
Humans
;
Kaplan-Meier Estimate
;
Liver Neoplasms/mortality/*radionuclide imaging/*surgery
;
Male
;
Middle Aged
;
Multimodal Imaging
;
Neoplasm Staging
;
*Positron-Emission Tomography
;
Predictive Value of Tests
;
Proportional Hazards Models
;
*Radiopharmaceuticals
;
Retrospective Studies
;
Risk Factors
;
Time Factors
;
Tomography, X-Ray Computed
;
Treatment Outcome